Cal Cohen

468 total citations
15 papers, 260 citations indexed

About

Cal Cohen is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Cal Cohen has authored 15 papers receiving a total of 260 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Infectious Diseases, 12 papers in Virology and 3 papers in Epidemiology. Recurrent topics in Cal Cohen's work include HIV Research and Treatment (12 papers), HIV/AIDS drug development and treatment (12 papers) and HIV/AIDS Research and Interventions (7 papers). Cal Cohen is often cited by papers focused on HIV Research and Treatment (12 papers), HIV/AIDS drug development and treatment (12 papers) and HIV/AIDS Research and Interventions (7 papers). Cal Cohen collaborates with scholars based in United States, United Kingdom and Spain. Cal Cohen's co-authors include Pablo Tebas, William G. Powderly, Keith Henry, Steven G. Deeks, Kristin Mondy, Andrew Phillips, John D. Baxter, Bernard Hirschel, Christoph Stephan and Zoë Fox and has published in prestigious journals such as Clinical Infectious Diseases, The Journal of Infectious Diseases and Molecules.

In The Last Decade

Cal Cohen

14 papers receiving 254 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Cal Cohen United States	8	219	158	91	34	11	15	260
Jorge Santana‐Bagur Puerto Rico	7	137 0.6×	101 0.6×	90 1.0×	40 1.2×	20 1.8×	16	208
Camilla Muccini Italy	9	164 0.7×	118 0.7×	42 0.5×	71 2.1×	9 0.8×	47	239
Àngels Masabeu Spain	8	176 0.8×	106 0.7×	71 0.8×	85 2.5×	7 0.6×	10	226
J Lange Netherlands	9	193 0.9×	147 0.9×	56 0.6×	55 1.6×	16 1.5×	17	248
Sorakij Bhakeecheep Thailand	11	302 1.4×	210 1.3×	93 1.0×	96 2.8×	12 1.1×	19	352
Rossana Ditangco Philippines	10	257 1.2×	160 1.0×	61 0.7×	110 3.2×	5 0.5×	16	300
Miquel Aranda Spain	3	254 1.2×	211 1.3×	146 1.6×	21 0.6×	13 1.2×	4	284
T. R. Sterling United States	7	141 0.6×	64 0.4×	47 0.5×	66 1.9×	6 0.5×	10	187
Sandy Griffith United States	10	442 2.0×	322 2.0×	78 0.9×	115 3.4×	23 2.1×	17	507
Yvon van Delft Netherlands	12	440 2.0×	354 2.2×	132 1.5×	79 2.3×	27 2.5×	28	481

Countries citing papers authored by Cal Cohen

Since Specialization

Citations

This map shows the geographic impact of Cal Cohen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cal Cohen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cal Cohen more than expected).

Fields of papers citing papers by Cal Cohen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cal Cohen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cal Cohen. The network helps show where Cal Cohen may publish in the future.

Co-authorship network of co-authors of Cal Cohen

This figure shows the co-authorship network connecting the top 25 collaborators of Cal Cohen. A scholar is included among the top collaborators of Cal Cohen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cal Cohen. Cal Cohen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

D’Antoni, Michelle L., et al.. (2025). Assessing phenotypic effect of integrase strand-transfer inhibitor (INSTI)-based resistance substitutions associated with failures on cabotegravir. Journal of Antimicrobial Chemotherapy. 80(4). 962–966. 2 indexed citations

Daar, Eric S., Chloe Orkin, Paul E. Sax, et al.. (2025). Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIV. AIDS Research and Therapy. 22(1). 45–45.

Castillo‐Mancilla, José, Mary Morrow, Peter W. Hunt, et al.. (2023). Beyond Undetectable: Modeling the Clinical Benefit of Improved Antiretroviral Adherence in Persons With Human Immunodeficiency Virus With Virologic Suppression. Open Forum Infectious Diseases. 10(5). ofad230–ofad230. 3 indexed citations

Feng, Joy Y., Venice Du Pont, Darius Babusis, et al.. (2022). The Nucleoside/Nucleotide Analogs Tenofovir and Emtricitabine Are Inactive against SARS-CoV-2. Molecules. 27(13). 4212–4212. 13 indexed citations

Erlandson, Kristine M., Christoph C Carter, Kathleen Melbourne, et al.. (2021). Weight Change Following Antiretroviral Therapy Switch in People With Viral Suppression: Pooled Data from Randomized Clinical Trials. Clinical Infectious Diseases. 73(8). 1440–1451. 81 indexed citations

Porter, Danielle, Alexander Thielen, Silvia Chang, et al.. (2015). Emergent HIV-1 Drug Resistance Mutations Were Not Present at Low-Frequency at Baseline in Non-Nucleoside Reverse Transcriptase Inhibitor-Treated Subjects in the STaR Study. Viruses. 7(12). 6360–6370. 15 indexed citations

Cohen, Cal, José Ramón Arribas, Kenneth R. Henry, et al.. (2012). STAR Study: single tablet regimen emtricitabine/rilpivirine/tenofovir DF is non‐inferior to efavirenz/emtricitabine/tenofovir DF in ART‐naïve adults. Journal of the International AIDS Society. 15(S4). 1–1. 25 indexed citations

Cohen, Cal, Jean‐Michel Molina, Pedro Cahn, et al.. (2010). Pooled week 48 safety and efficacy results from the ECHO and THRIVE phase III trials comparing TMC278 vs EFV in treatment‐naïve, HIV‐1‐infected patients. Journal of the International AIDS Society. 13(S4). 13 indexed citations

Fox, Zoë, Andrew Phillips, Cal Cohen, et al.. (2008). Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen. AIDS. 22(17). 2279–2289. 49 indexed citations

10.

Hill, Andrew, et al.. (2007). Modelling-Based Prediction of Clinical Benefits from Etravirine in the TMC125-C223 Trial. HIV Clinical Trials. 8(2). 68–76. 1 indexed citations

11.

Phillips, Andrew, Cal Cohen, & Jens Lundgren. (2006). Issues in the design of trials comparing management strategies for heavily pretreated patients. Current Opinion in HIV and AIDS. 1(6). 476–481. 1 indexed citations

12.

Griffiths, P. D., Lawrence Corey, Cal Cohen, et al.. (2004). Lessons from HIV and hepatitis viruses. Antiviral Research. 63. S11–S18. 1 indexed citations

13.

Tebas, Pablo, Keith Henry, Kristin Mondy, et al.. (2002). Effect of Prolonged Discontinuation of Successful Antiretroviral Therapy on CD4⁺T Cell Decline in Human Immunodeficiency Virus–Infected Patients: Implications for Intermittent Therapeutic Strategies. The Journal of Infectious Diseases. 186(6). 851–854. 43 indexed citations

14.

Elion, Richard, et al.. (1999). An open-label trial of stavudine, lamivudine and efavirenz in the treatment of HIV-positive, treatment-naive patients, and implications for clinical practice.. PubMed. 4 Suppl 3. 89–91. 1 indexed citations

15.

Beck, Eduard J., Colin Kenny, Cal Cohen, et al.. (1990). An update on HIV-testing at a London sexually transmitted diseases clinic: long-term impact of the AIDS media campaigns.. Sexually Transmitted Infections. 66(3). 142–147. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact